The present invention relates to a method of directly detecting, using a mass-spectrometry method, whether a microorganism contained in a sample is resistant to antibiotics, and a kit for detection used therewith. More particularly, the present invention relates to a method and kit for directly detecting an antibiotic hydrolase secreted by a microorganism resistant to antibiotics, thereby directly determining whether the microorganism is resistant to antibiotics. According to the present invention, it is possible to very simply and immediately confirm whether a specific strain is resistant to antibiotics in the field. In particular, a complicated pretreatment process such as proteolysis is not performed, and a complicated identification process of calibrating and then combining the obtained results is not performed. Accordingly, it is possible to realize a method of easily confirming whether antibiotic resistance occurs in just a dozen minutes, compared to a conventional technology in which it takes several days to confirm whether antibiotic resistance occurs, and a simple diagnostic kit used therewith.

The present invention relates to a method for improving the therapeutic efficacy of an anticancer agent, comprising administering to a subject in need thereof an effective amount of an adsorbent or an antibiotic-inactivating enzyme.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.

A novel technique for reducing the mis-cleavage of the TorA signal peptide, and thereby a method for efficient secretory production of a heterologous protein by a coryneform bacterium using a TorA signal peptide is provided. A coryneform bacterium having an ability of secretory production of a heterologous protein using a TorA signal peptide and has been modified so that the activity of a LepB protein is increased is cultured to produce the heterologous protein by secretory production.

The present invention provides, in part, therapeutic beta-lactamases that can, inter alia, mitigate antibiotic resistance.

The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a Verona integron-encoded metallo-β-lactamase (VIM-2) variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.

A peptide cyclase that has the amino acid sequence represented by SEQ ID NO: 1 or a mutated sequence thereof, or a peptide cyclase that has an amino acid sequence encoded by a base sequence encoding the amino acid sequence represented by SEQ ID NO: 1 or a mutated sequence thereof; DNA encoding the peptide cyclase; a method for producing the peptide cyclase; and a method for producing a cyclic peptide using the peptide cyclase.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.